BPTH has been the topic of several other research reports. Zacks Investment Research cut shares of Bio-Path Holdings from a buy rating to a hold rating in a research report on Wednesday, July 12th. Maxim Group set a $2.00 price target on shares of Bio-Path Holdings and gave the stock a buy rating in a research report on Wednesday, April 5th.
Shares of Bio-Path Holdings (NASDAQ:BPTH) opened at 0.351 on Thursday. The stock has a 50 day moving average of $0.39 and a 200 day moving average of $0.63. Bio-Path Holdings has a 12-month low of $0.32 and a 12-month high of $1.74. The company’s market cap is $33.57 million.
Bio-Path Holdings (NASDAQ:BPTH) last issued its quarterly earnings results on Thursday, May 11th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.01. Analysts forecast that Bio-Path Holdings will post ($0.07) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/bio-path-holdings-inc-nasdaqbpth-earns-buy-rating-from-hc-wainwright-updated-updated/1252665.html.
A number of hedge funds have recently modified their holdings of the stock. Legal & General Group Plc boosted its stake in Bio-Path Holdings by 5,474.3% in the second quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock worth $681,000 after buying an additional 1,741,978 shares during the last quarter. HighTower Advisors LLC boosted its stake in Bio-Path Holdings by 9.1% in the first quarter. HighTower Advisors LLC now owns 1,263,070 shares of the company’s stock worth $1,043,000 after buying an additional 105,000 shares during the last quarter. Sabby Management LLC boosted its stake in Bio-Path Holdings by 3.5% in the first quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock worth $569,000 after buying an additional 23,352 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Bio-Path Holdings by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after buying an additional 5,172 shares during the last quarter. Finally, Tower Research Capital LLC TRC bought a new stake in Bio-Path Holdings during the first quarter worth $105,000. 19.90% of the stock is currently owned by hedge funds and other institutional investors.
Bio-Path Holdings Company Profile
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with our FREE daily email newsletter.